(continue reading for full post)
CDK inhibitor in development for multiple myeloma by Astex Pharma $ASTX
There and back again: fragments and BACE-1
Focused on the Schering-Plough/Merck drug discovery program targeting BACE for Alzheimer's
Pushing the Rule of 3
ASTX scientists publish a guideline for successful fragment-based discovery
Fragments vs. Pharma
When fragment-based discovery and big pharma go after the same kinase targets, how are the resulting drug candidates similar and different?
Experiences in fragment-based drug discovery
Concepts and challenges in drug discovery, reviewing examples targeting b-Raf (Plexxikon), HSP90 (Astex), and BACE (Merck/Schering Plough)
Fragments vs Hepatitis C NS3
Updates and data related to ASTX's preclinical HCV program